OTCPK:RTNX.F

Stock Analysis Report

Executive Summary

Renalytix AI plc focuses on the development of artificial intelligence enabled clinical diagnostic solutions for kidney disease.


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Renalytix AI's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RTNX.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

RTNX.F

-3.3%

US Healthcare Services

-2.7%

US Market


1 Year Return

n/a

RTNX.F

25.1%

US Healthcare Services

21.2%

US Market

Return vs Industry: Insufficient data to determine how RTNX.F performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how RTNX.F performed against the US Market.


Shareholder returns

RTNX.FIndustryMarket
7 Day0%-3.3%-2.7%
30 Day0%2.0%0.09%
90 Day28.4%7.1%6.9%
1 Yearn/a25.4%25.1%23.8%21.2%
3 Yearn/a83.5%82.7%48.1%38.6%
5 Yearn/a63.2%61.7%72.5%53.4%

Price Volatility Vs. Market

How volatile is Renalytix AI's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Renalytix AI undervalued compared to its fair value and its price relative to the market?

8.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RTNX.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RTNX.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RTNX.F is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: RTNX.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RTNX.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RTNX.F is overvalued based on its PB Ratio (8.2x) compared to the US Healthcare Services industry average (3.7x).


Next Steps

Future Growth

How is Renalytix AI forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

26.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Renalytix AI has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Renalytix AI performed over the past 5 years?

-343.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: RTNX.F is currently unprofitable.

Growing Profit Margin: RTNX.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if RTNX.F's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare RTNX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RTNX.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (0.6%).


Return on Equity

High ROE: RTNX.F has a negative Return on Equity (-19.74%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Renalytix AI's financial position?


Financial Position Analysis

Short Term Liabilities: RTNX.F's short term assets ($9.4M) exceed its short term liabilities ($755.0K).

Long Term Liabilities: RTNX.F has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: RTNX.F is debt free.

Reducing Debt: RTNX.F had no debt 5 years ago.

Debt Coverage: RTNX.F has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: RTNX.F has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: RTNX.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if RTNX.F's debt is covered by short term assets.


Next Steps

Dividend

What is Renalytix AI's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage0.7%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate RTNX.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RTNX.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RTNX.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RTNX.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RTNX.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Renalytix AI's salary, the management and board of directors tenure and is there insider trading?


CEO

James McCullough (51yo)

0yrs

Tenure

0

Mr. James R. McCullough, MBA, has been Chief Executive Officer and Director of Renalytix AI plc. Mr. McCullough serves as Director at LungLife AI, Inc. (Cynvenio Biosystems, Inc). Mr. McCullough co-founded ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$160,18826 Apr 19
Hay & Robertson plc
EntityCompany
Shares100,074
Max PriceUS$1.62

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Tom McLain (60yo)

    President & Chief Commercial Officer

    • Tenure: 0.5yrs
  • James McCullough (51yo)

    CEO & Director

    • Oliver Sterling

      Chief Financial Officer

      • Michael Donovan

        Chief Medical Officer

        • Sally Bowden

          Chief Operating Officer

          • Salim Hamir

            Company Secretary

            • Fergus Fleming (51yo)

              CTO & Director

              • BJ Singh

                Head of Clinical Operations

                • Tenure: 0.08yrs

              Board Members

              • James McCullough (51yo)

                CEO & Director

                • Julian Baines (54yo)

                  Non-Executive Chairman

                  • Erik Lium (50yo)

                    Non-executive Director

                    • Tenure: 1.2yrs
                  • Chris Mills (65yo)

                    Non-executive Director

                    • Richard Evans (62yo)

                      Non-executive Director

                      • Barbara Murphy (63yo)

                        Chair of Advisory Board & Non-executive Director

                        • Fergus Fleming (51yo)

                          CTO & Director

                          • Steven Coca

                            Member of Advisory Board

                            • Girish Nadkarni

                              Member of Advisory Board

                              • Chirag Parikh (45yo)

                                Chair of Advisory Board & Director

                                Company Information

                                Renalytix AI plc's company bio, employee growth, exchange listings and data sources


                                Key Information

                                • Name: Renalytix AI plc
                                • Ticker: RTNX.F
                                • Exchange: OTCPK
                                • Founded: 2018
                                • Industry: Health Care Technology
                                • Sector: Healthcare
                                • Market Cap: UK£207.956m
                                • Listing Market Cap: UK£270.126m
                                • Shares outstanding: 59.42m
                                • Website: https://www.renalytixai.com

                                Number of Employees


                                Location

                                • Renalytix AI plc
                                • Avon House
                                • 19 Stanwell Road
                                • Cardiff
                                • South Glamorgan
                                • CF64 2EZ
                                • United Kingdom

                                Listings

                                TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
                                RENXAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPNov 2018
                                RTNX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2018

                                Biography

                                Renalytix AI plc focuses on the development of artificial intelligence enabled clinical diagnostic solutions for kidney disease. Its solutions are used in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was incorporated in 2018 and is headquartered in Cardiff, the United Kingdom. 


                                Company Analysis and Financial Data Status

                                All financial data provided by Standard & Poor's Capital IQ.
                                DataLast Updated (UTC time)
                                Company Analysis2020/01/29 01:13
                                End of Day Share Price2019/12/06 00:00
                                Earnings2019/06/30
                                Annual Earnings2019/06/30


                                Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.